Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 14,325,692 | $527,042,209 | +6% | 2.27% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 9,364,972 | $344,537,320 | +18% | 3.34% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 4,982,384 | $183,301,907 | 6.55% | |
| 4. | Holocene Advisors Brandon Haley | 3,632,952 | $133,656,304 | -2% | 0.33% |
| 5. | Deerfield Management James E. Flynn | 3,384,072 | $124,500,009 | +3% | 2.26% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | $34,999,974.00 | 760,869 | 2024-12-05 | Filing | |
| $46.00 | 543,478 | $24,999,988.00 | 2,096,612 | 2024-12-05 | Filing | |
| $20.85 | 6,200 | $129,270.00 | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | $1,916,334.00 | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | $6,999,982.00 | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.61 | 1,912 | $75,735.85 | 54,093 | 2025-06-20 | Filing | |
| $39.83 | 3,510 | $139,803.30 | 150,675 | 2025-06-16 | Filing | |
| $39.83 | 13,496 | $537,545.68 | 428,720 | 2025-06-16 | Filing | |
| $39.83 | 1,878 | $74,800.74 | 56,005 | 2025-06-16 | Filing | |
| $39.83 | 2,170 | $86,431.10 | 113,314 | 2025-06-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,761,691 | $579,872,613 | 0.01% | |
| 2. | 10,590,727 | $389,682,579 | 0.19% | |
| 3. | 10,259,738 | $377,455,760 | 0.07% | |
| 4. | 8,661,393 | $318,652,648 | 0.01% | |
| 5. | 8,325,184 | $306,283,536 | 0.02% |
News See All
11 Best Upside Stocks to Invest in Now
Earlier on July 17, Sharmin Mossavar-Rahmani, Goldman Sachs CIO of wealth management, joined 'Squawk Box' on CNBC to discuss the latest market trends, what to expect in H2 2025, the state of the economy...
Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q2 2025 Earnings Conference Call.
Revolution Medicines, Iambic Therapeutics Partner to Use AI for Novel RAS-Addicted Cancer Drug Discovery
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Revolution Medicines' Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
Billionaire Hedge Funds
